AriBio to Hold Press Conference on AR1001 Global Phase 3 Trial on Nov. 23; Samjin Pharm, China's Fosun to Attend View original image

AriBio will hold a press conference to explain the results of the global Phase 3 trial of AR1001, an oral Alzheimer's disease drug candidate, and its commercialization strategy. Representatives from its domestic partner Samjin Pharm and Chinese partner Fosun Pharma will also attend to share their plans for global commercialization cooperation.


AriBio said on November 19 that it would hold the press conference on November 23 to discuss the main results of the global Phase 3 trial of AR1001 and its plans for further development and commercialization.


A key point of interest in the trial is the result for the monotherapy group, whose members had not taken existing Alzheimer's disease treatments. An analysis of 604 such patients found that, at week 52, clinical worsening in the AR1001 group was delayed by 31% compared with the placebo group, achieving statistical significance.


The trial was designed in advance so that it would meet its primary efficacy endpoint if statistical significance was achieved in either the overall patient population or the monotherapy group. Accordingly, the company said that even though statistical significance was not confirmed in the overall patient population, the prespecified results for the monotherapy group could be used as evidence in support of regulatory approval.


Dr. David Greeley, who participated in AR1001's Phase 2 trial and helped design Phase 3, recently described the monotherapy group's results in a public interview as "a result close to a home run." Emphasizing that the analysis of the monotherapy group had been planned in advance rather than conducted after the fact, he said the company should actively pursue approval from the U.S. Food and Drug Administration (FDA), citing the convenience and accessibility of an oral treatment.


Jang Seonghun, head of the Global Regulatory Consulting Business Unit at the Korea National Enterprise for Clinical Trials and a former FDA official, also called the trial design "smart" in an interview with domestic media. He explained that although significance was not confirmed in the overall patient population, the results achieved in the prespecified monotherapy group could provide a basis for seeking approval for that patient group.


The press conference will also be attended by the head of domestic partner Samjin Pharm and representatives of China's Fosun Pharma. Samjin Pharm President Kim Sangjin previously said he considered AR1001's clinical results a success. He also said that the company had agreed to work with Fosun Pharma's chief executive officer (CEO) to accelerate commercialization.


At the press conference, AriBio plans to discuss the clinical results for the monotherapy group, its plans to pursue FDA approval, and its global commercialization strategy. The company intends to develop specific development and commercialization strategies together with its domestic and international partners.



An AriBio representative said, "With assessments from key researchers and the participation of our domestic and international partners, we will deepen understanding of AR1001's clinical results and develop specific plans for its further development and commercialization."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing